Iovance Biotherapeutics (IOVA) Stock Analysis & Winston Score

Iovance Biotherapeutics is a biotech company that makes cancer treatments using a patient's own immune cells. Its main product, Amtagvi (lifileucel), is approved in the United States to treat advanced melanoma, a serious form of skin cancer. Iovance is notable for being the first company to win FDA approval for a tumor-infiltrating lymphocyte (TIL) therapy, which is a type of personalized cell therapy. The company makes money by selling Amtagvi to hospitals and cancer treatment centers. Each treatment is custom-made from a patient's own tumor tissue, which makes it expensive to manufacture but also hard for competitors to copy quickly. Iovance operates primarily in the United States and is still in an early commercial stage, spending far more than it earns — reflected in its deeply negative operating margin. The key growth driver is expanding Amtagvi's use into other cancers like cervical cancer, but the main risk is whether the company can scale manufacturing and reach profitability before needing to raise more cash.